Page 2 - Jonae Barnes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Atea Pharmaceuticals, Inc : Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

Atea Pharmaceuticals, Inc : Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJean pierre sommadossiJonae barnesAtea pharmaceuticalsCorporate communicationsAtea pharmaceuticals incFounder of atea pharmaceuticalsFirst clinical dataRuzasvir show combination was well toleratedRuzasvir were not affectedConcomitant dosingIndicating low riskDrug interactionsPotent direct acting antivirals in vitroFavorable antiviral profiles againstResistant associated variants

Atea Pharmaceuticals, Inc (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript

Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions].

United statesJon millerAndrea corcoranMaxwell skorJanet hammondJohn vavrickaArantxa horgaDeric josephJonae barnesJean pierre sommadossiJonathan millerRoanna ruizAtea pharmaceuticalsMorgan stanleyCorporate communications at atea pharmaceuticalsAtea pharmaceuticals inc

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJonae barnesCompany presentation onCorporate communicationsAtea pharmaceuticals incAtea pharmaceuticalsWhile the companyLondon healthcare conferenceCompany presentationAnnual evercoreFireside chatAtea pharmaceuticalPrivate securities litigation reform actQuarterly reportInvestor relationsO connorstern investor relations

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

05.06.2023 - BOSTON, June 05, 2023 (GLOBE NEWSWIRE) - Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today .

Jonae barnesAtea pharmaceuticalsCorporate communicationsWhile the companyAbout ateaPrivate securities litigation reform actQuarterly reportInvestor relations

Atea Pharmaceuticals (AVIR) Confirms $5 75/sh + CVR Acquisition Proposal from Tang Capital Partners Affiliate, Concentra Biosciences

Atea Pharmaceuticals (AVIR) Confirms $5 75/sh + CVR Acquisition Proposal from Tang Capital Partners Affiliate, Concentra Biosciences
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jonae barnesConcentra biosciencesCorporate communicationsAtea pharmaceuticals incAtea pharmaceuticalsTang capitalTang capital partnerPrivate securities litigation reform actAnnual reportInvestor relationsO connorstern investor relations